Ascentage Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ascentage Pharma Group
AAPG Stock   23.82  0.62  2.67%   
Ascentage Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ascentage Pharma's valuation are provided below:
Gross Profit
354.9 M
Profit Margin
(2.97)
Market Capitalization
2.2 B
Enterprise Value Revenue
40.0643
Revenue
390.6 M
There are over one hundred nineteen available fundamental signals for Ascentage Pharma Group, which can be analyzed over time and compared to other ratios. Active traders should verify all of Ascentage Pharma Group prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. The Ascentage Pharma's current Market Cap is estimated to increase to about 36.2 B. The Ascentage Pharma's current Enterprise Value is estimated to increase to about 36.6 B

Ascentage Pharma Total Revenue

1.18 Billion

Check Ascentage Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ascentage Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 112.5 M, Interest Expense of 41.4 M or Selling General Administrative of 117.8 M, as well as many indicators such as Price To Sales Ratio of 42.69, Dividend Yield of 0.0 or PTB Ratio of 137. Ascentage financial statements analysis is a perfect complement when working with Ascentage Pharma Valuation or Volatility modules.
  
Build AI portfolio with Ascentage Stock
Check out the analysis of Ascentage Pharma Correlation against competitors.

Ascentage Pharma Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2 B3 B1.5 B
Slightly volatile
Short and Long Term Debt Total2 B1.9 B644.6 M
Slightly volatile
Other Current Liabilities172.4 M266.7 M136.4 M
Slightly volatile
Total Current Liabilities1.4 B1.3 B429.4 M
Slightly volatile
Property Plant And Equipment Net1.1 B1 B363.6 M
Slightly volatile
Current Deferred Revenue65.3 M62.2 M15.9 M
Slightly volatile
Accounts Payable111 M105.8 M34.9 M
Slightly volatile
Cash1.1 B1.4 B758.8 M
Slightly volatile
Non Current Assets Total737.3 M1.3 B521.3 M
Slightly volatile
Non Currrent Assets Other80.9 M67.9 M52.4 M
Slightly volatile
Cash And Short Term Investments1.1 B1.4 B851.1 M
Slightly volatile
Net Receivables119.6 M113.9 M40.4 M
Slightly volatile
Good Will19.8 M22.2 M24.3 M
Slightly volatile
Common Stock Shares Outstanding364.7 M347.4 M105.1 M
Slightly volatile
Short Term Investments4.6 M4.8 M93.8 M
Slightly volatile
Liabilities And Stockholders Equity2 B3 B1.5 B
Slightly volatile
Non Current Liabilities Total1.2 B1.4 B899.1 M
Slightly volatile
Other Current Assets159.3 M151.7 M51.8 M
Slightly volatile
Total Liabilities1.7 B2.7 B1.3 B
Slightly volatile
Total Current Assets1.2 B1.7 B936.5 M
Slightly volatile
Short Term Debt940.7 M895.9 M234.4 M
Slightly volatile
Intangible Assets69.7 M68.4 M85 M
Slightly volatile
Common Stock177.3 K246.1 K120.9 K
Slightly volatile
Long Term Debt1.1 B998.9 M681.5 M
Slightly volatile
Capital Lease Obligations22 M34.8 M16.2 M
Slightly volatile
Net Invested Capital2.1 B2.2 B1.6 B
Slightly volatile
Property Plant And Equipment Gross953.8 M1.3 B671.6 M
Slightly volatile
Short and Long Term Debt929.3 M885.1 M249 M
Slightly volatile
Capital Stock203.1 K246.1 K171.3 K
Slightly volatile
Net Working Capital263 M276.8 M727.6 M
Slightly volatile
Long Term Investments27.3 M38.9 M27.7 M
Very volatile
Non Current Liabilities Other5 M5.6 M6.2 M
Slightly volatile

Ascentage Pharma Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization112.5 M107.1 M30.8 M
Slightly volatile
Interest Expense41.4 M74.1 M27.9 M
Slightly volatile
Selling General Administrative117.8 M215.2 M82.6 M
Slightly volatile
Total Revenue1.2 B1.1 B226.2 M
Slightly volatile
Gross Profit1.1 B1.1 B216.9 M
Slightly volatile
Other Operating Expenses1.6 B1.6 B602.7 M
Slightly volatile
Research Development570 M1.1 B408.2 M
Slightly volatile
Cost Of Revenue35.1 M33.4 M9.6 M
Slightly volatile
Total Operating Expenses1.6 B1.5 B589.6 M
Slightly volatile
Selling And Marketing Expenses236.7 M225.4 M62.7 M
Slightly volatile
Interest Income45.7 M43.5 M13.7 M
Slightly volatile
Reconciled Depreciation67.1 M107.1 M44.3 M
Slightly volatile

Ascentage Pharma Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation35.9 M18.8 M48.9 M
Slightly volatile
Begin Period Cash Flow876.8 M1.2 B564.1 M
Slightly volatile
Depreciation112.5 M107.1 M33 M
Slightly volatile
Capital Expenditures26.5 M27.9 M72.7 M
Slightly volatile
Total Cash From Financing Activities723.6 M362 M565.8 M
Pretty Stable
End Period Cash Flow978.9 M1 B693.1 M
Slightly volatile
Issuance Of Capital Stock470.2 M480.5 M601.9 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio42.6944.93525
Slightly volatile
Days Sales Outstanding40.2942.41281
Slightly volatile
Stock Based Compensation To Revenue0.02330.02454.7215
Slightly volatile
Capex To Depreciation0.280.311.704
Slightly volatile
EV To Sales43.1745.44495
Slightly volatile
Inventory Turnover4.173.971.584
Slightly volatile
Days Of Inventory On Hand90.4595.21341
Slightly volatile
Payables Turnover0.460.360.8301
Slightly volatile
Sales General And Administrative To Revenue0.210.222.9783
Pretty Stable
Research And Ddevelopement To Revenue1.061.1115.5197
Pretty Stable
Capex To Revenue0.02710.02853.324
Pretty Stable
Cash Per Share3.53.6811.6893
Pretty Stable
Days Payables Outstanding1.3 K1.3 K1.6 K
Slightly volatile
Income Quality0.310.320.5436
Pretty Stable
Intangibles To Total Assets0.0420.04420.119
Slightly volatile
Current Ratio1.381.454.5563
Slightly volatile
Receivables Turnover9.358.914.3345
Slightly volatile
Capex Per Share0.06880.07241.1464
Slightly volatile
Revenue Per Share3.072.921.0469
Slightly volatile
Interest Debt Per Share8.235.166.2615
Slightly volatile
Debt To Assets0.60.570.2335
Slightly volatile
Operating Cycle131138343
Pretty Stable
Days Of Payables Outstanding1.3 K1.3 K1.6 K
Slightly volatile
Ebt Per Ebit2.011.231.4911
Pretty Stable
Long Term Debt To Capitalization0.530.690.4759
Slightly volatile
Quick Ratio1.371.454.5531
Slightly volatile
Net Income Per E B T0.790.920.9738
Slightly volatile
Cash Ratio1.161.223.2275
Slightly volatile
Days Of Inventory Outstanding90.4595.21341
Slightly volatile
Days Of Sales Outstanding40.2942.41281
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.021.11.1766
Slightly volatile
Fixed Asset Turnover1.311.240.9835
Slightly volatile
Debt Ratio0.60.570.2335
Slightly volatile
Price Sales Ratio42.6944.93525
Slightly volatile
Asset Turnover0.350.340.0802
Slightly volatile
Gross Profit Margin0.720.870.9041
Slightly volatile

Ascentage Pharma Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap36.2 B34.5 B11.8 B
Slightly volatile
Enterprise Value36.6 B34.9 B11.7 B
Slightly volatile

Ascentage Fundamental Market Drivers

About Ascentage Pharma Financial Statements

Ascentage Pharma stakeholders use historical fundamental indicators, such as Ascentage Pharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although Ascentage Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ascentage Pharma's assets and liabilities are reflected in the revenues and expenses on Ascentage Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ascentage Pharma Group. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue62.2 M65.3 M
Total Revenue1.1 B1.2 B
Cost Of Revenue33.4 M35.1 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.22  0.21 
Research And Ddevelopement To Revenue 1.11  1.06 
Capex To Revenue 0.03  0.03 
Revenue Per Share 2.92  3.07 
Ebit Per Revenue(0.34)(0.36)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Stock, refer to the following important reports:
How To Invest In Ascentage
Details
Is Ascentage Stock a good investment?
Details
What is Ascentage Pharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ascentage Pharma Correlation against competitors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Can Biotechnology industry sustain growth momentum? Does Ascentage have expansion opportunities? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Ascentage Pharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(2.10)
Revenue Per Share
4.78
Quarterly Revenue Growth
(0.72)
Return On Assets
(0.23)
Return On Equity
(1.60)
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Ascentage Pharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Ascentage Pharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Ascentage Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY